Abstract Library

#3037 Effects of Debulking Surgery, Transarterial Embolisation (TAE) and Transarterial Chemoembolisation (TACE) on Quality of Life in Patients with Metastatic Ileal and Pancreatic Neuroendocrine Tumours (NETs)

Introduction: Debulking surgery, TAE and TACE procedures are undertaken in patients with metastatic NETs. Reducing the physical burden of disease may prolong survival and can improve the quality of life of patients. However, there is only limited quality of life data available after surgery despite the fact that is has been used routinely for many years.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Sinclair A, Tanno L, Jarvis E, Ramsey E, Naheed S,

Keywords: Quality of Life, Debulking Surgery, TAE, TACE, Metastatic, NETs,

#2787 64Cu-DOTATATE PET/CT Imaging of Patients with Neuroendocrine Neoplasms Can Be Performed between 1 and 3 Hours after Radiotracer Injection: Comparison of Lesion Detection Ability and Contrast

Introduction: PET/CT imaging of patients with neuroendocrine neoplasms (NEN) 1 hour (h) post injection (pi) of 64Cu-DOTATATE has shown superiority in lesion detection when compared to other clinically available somatostatin receptor imaging (SRI) modalities.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Loft M, Johannesen H, Carlsen E, Johnbeck C, Binderup T,

Keywords: 64Cu-DOTATATE, Neuroendocrine Neoplasms, PET Imaging, Somatostatin Receptor Imaging,

#2692 Development of Ex-Vivo Models of Metastatic Neuroendocrine Neoplasms

Introduction: The lack of relevant in-vivo and in-vitro models has precluded investigations of the pathophysiology of metastatic NENs. Organotypic tumour slices retain the complexity of tumours in-vivo without extensive manipulation of the tissue.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Srirajaskanthan R

Authors: Srirajaskanthan R, Doornebal E, Harris N, Zen Y, Pizanias M,

Keywords: ex-vivo, organotypic tumour slices, immune environment, models,

#2210 213 Bi and Ac 225 DOTATOC Receptor Labeled Targeted Alpha-Radionuclide Therapy in Neuroendocrine Tumors Refractory to Beta Radiation - Early Experience

Introduction: Radiopeptide therapy using a somatostatin analogue labeled with alpha emitters Actinium 225 and Bismuth 213 DOTATOC is a novel therapeutic option in metastatic neuroendocrine tumors (NET), with few alternative therapeutic options for patients with beta refractory disease. We report the first experience with 213Bi and Ac225 DOTATOC targeted alpha therapy (TAT) in treatment of well differentiated metastatic NETs at a tertiary care hospital in India.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Dureja S

Authors: Dureja S, Sen I, Pant V, Thak P,

Keywords: Targeted alpha therapy, TAT, PRRT, neuroendocrine tumors, beta refractory,

#2178 Nutritional Status and Considerations for Patients Diagnosed with a Gastroenteropancreatic Neuroendocrine Tumor: Preliminary Baseline Characteristics from the Nutrition in NETs Study

Introduction: Gastroenteropancreatic neuroendocrine tumours (GEP NET) cause various symptoms impacting on nutritional status and diet. Published data indicates up to 25% of GEP NET patients are malnourished, and dietary change is prevalent. Further research is required to guide nutrition recommendations.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Kennedy E

Authors: Kennedy E, Kiss N, Michael M, Gough K, Drosdowsky A,

Keywords: nutrition, malnutrition, diet, neuroendocrine,